Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung07 in first-line advanced non-squamous NSCLC
jRCT2061220066Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of darunavir + cobicistat, pembrolizumab, carboplatin, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Progression-free survival by blinded independent central review in all randomized participants, Progression-free survival by blinded independent central review in TROP2 NMR-positive randomized participants and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061220066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220066.